These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30012779)

  • 1. Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial.
    Antonsen KK; Klausen MK; Brunchmann AS; le Dous N; Jensen ME; Miskowiak KW; Fisher PM; Thomsen GK; Rindom H; Fahmy TP; Vollstaedt-Klein S; Benveniste H; Volkow ND; Becker U; Ekstrøm C; Knudsen GM; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2018 Jul; 8(7):e019562. PubMed ID: 30012779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
    Klausen MK; Jensen ME; Møller M; Le Dous N; Jensen AØ; Zeeman VA; Johannsen CF; Lee A; Thomsen GK; Macoveanu J; Fisher PM; Gillum MP; Jørgensen NR; Bergmann ML; Enghusen Poulsen H; Becker U; Holst JJ; Benveniste H; Volkow ND; Vollstädt-Klein S; Miskowiak KW; Ekstrøm CT; Knudsen GM; Vilsbøll T; Fink-Jensen A
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36066977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
    Larsen JR; Vedtofte L; Holst JJ; Oturai P; Kjær A; Correll CU; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2014 Mar; 4(3):e004227. PubMed ID: 24667381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial).
    Jensen ME; Stenbæk DS; Juul TS; Fisher PM; Ekstrøm CT; Knudsen GM; Fink-Jensen A
    BMJ Open; 2022 Oct; 12(10):e066019. PubMed ID: 36241352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.
    Thomsen M; Holst JJ; Molander A; Linnet K; Ptito M; Fink-Jensen A
    Psychopharmacology (Berl); 2019 Feb; 236(2):603-611. PubMed ID: 30382353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
    Ishøy PL; Knop FK; Broberg BV; Baandrup L; Fagerlund B; Jørgensen NR; Andersen UB; Rostrup E; Glenthøj BY; Ebdrup BH
    BMJ Open; 2014 Jan; 4(1):e004158. PubMed ID: 24401727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial.
    Yammine L; Verrico CD; Versace F; Webber HE; Suchting R; Weaver MF; Kosten TR; Alibhai H; Cinciripini PM; Lane SD; Schmitz JM
    BMJ Open; 2023 Jun; 13(6):e072707. PubMed ID: 37316311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
    Sass MR; Danielsen AA; Köhler-Forsberg O; Storgaard H; Knop FK; Nielsen MØ; Sjödin AM; Mors O; Correll CU; Ekstrøm C; Vinberg M; Nielsen J; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2023 Jan; 13(1):e068652. PubMed ID: 36720576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASF (a Compound of Traditional Chinese Medicine) in the treatment of patients with alcohol dependence: Study protocol of a randomized, double-blinded, placebo-controlled clinical trial.
    Liang X; Hu X; Zhang X; Fu H
    Medicine (Baltimore); 2020 Dec; 99(52):e23899. PubMed ID: 33350787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.
    Freet CS; Evans B; Brick TR; Deneke E; Wasserman EJ; Ballard SM; Stankoski DM; Kong L; Raja-Khan N; Nyland JE; Arnold AC; Krishnamurthy VB; Fernandez-Mendoza J; Cleveland HH; Scioli AD; Molchanow A; Messner AE; Ayaz H; Grigson PS; Bunce SC
    Addict Sci Clin Pract; 2024 Jul; 19(1):56. PubMed ID: 39061093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.
    Jensterle M; Ferjan S; Battelino T; Kovač J; Battelino S; Šuput D; Vovk A; Janež A
    Trials; 2021 Jul; 22(1):464. PubMed ID: 34281590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
    Vijiaratnam N; Girges C; Auld G; Chau M; Maclagan K; King A; Skene S; Chowdhury K; Hibbert S; Morris H; Limousin P; Athauda D; Carroll CB; Hu MT; Silverdale M; Duncan GW; Chaudhuri R; Lo C; Del Din S; Yarnall AJ; Rochester L; Gibson R; Dickson J; Hunter R; Libri V; Foltynie T
    BMJ Open; 2021 May; 11(5):e047993. PubMed ID: 34049922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Diamant M; Pieters-van den Bos IC; van Raalte DH; Cahen DL
    Diabetes Obes Metab; 2016 Mar; 18(3):281-8. PubMed ID: 26640129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice.
    Thomsen M; Dencker D; Wörtwein G; Weikop P; Egecioglu E; Jerlhag E; Fink-Jensen A; Molander A
    Pharmacol Biochem Behav; 2017 Sep; 160():14-20. PubMed ID: 28778739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.
    Suchankova P; Yan J; Schwandt ML; Stangl BL; Caparelli EC; Momenan R; Jerlhag E; Engel JA; Hodgkinson CA; Egli M; Lopez MF; Becker HC; Goldman D; Heilig M; Ramchandani VA; Leggio L
    Transl Psychiatry; 2015 Jun; 5(6):e583. PubMed ID: 26080318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual reality-assisted cognitive behavioural therapy for outpatients with alcohol use disorder (CRAVR): a protocol for a randomised controlled trial.
    Thaysen-Petersen D; Hammerum SK; Vissing AC; Arnfred BT; Nordahl R; Adjorlu A; Nordentoft M; Oestrich IH; Düring SW; Fink-Jensen A
    BMJ Open; 2023 Mar; 13(3):e068658. PubMed ID: 36990475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.
    Sørum ME; Gang AO; Tholstrup DM; Gudbrandsdottir S; Kissow H; Kornblit B; Müller K; Knop FK
    BMJ Open; 2024 Oct; 14(10):e089862. PubMed ID: 39384243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial.
    Wiberg S; Kjaergaard J; Møgelvang R; Møller CH; Kandler K; Ravn H; Hassager C; Køber L; Nilsson JC
    BMJ Open; 2021 Nov; 11(11):e052340. PubMed ID: 34740932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
    Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
    Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.